Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Glofit-GemOx-P for relapsed or refractory diffuse large B-cell lymphoma
ChiCTR2600135840Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab, gemcitabine, oxaliplatin, pirtobrutinib and obinutuzumab in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Best complete response rate. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
glofitamabgemcitabineoxaliplatinpirtobrutinibobinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600135840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135840.